ANIPRYL- selegiline hydrochloride tablet

国: アメリカ合衆国

言語: 英語

ソース: NLM (National Library of Medicine)

有効成分:

SELEGILINE HYDROCHLORIDE (UNII: 6W731X367Q) (SELEGILINE - UNII:2K1V7GP655)

から入手可能:

Zoetis Inc.

INN（国際名）:

SELEGILINE HYDROCHLORIDE

構図:

SELEGILINE HYDROCHLORIDE 2 mg

投与経路:

ORAL

処方タイプ:

PRESCRIPTION

適応症:

Anipryl tablets are indicated for the control of clinical signs associated with canine cognitive dysfunction syndrome (CDS) and control of clinical signs associated with uncomplicated canine pituitary dependent hyperadrenocorticism (PDH). Anipryl is contraindicated in patients with known hypersensitivity to this drug.  In humans, selegiline is contraindicated for use with meperidine and this contraindication is often extended to other opioids.

製品概要:

Four tablet strengths are available in blister-packs of 30 tablets each: 5 mg, 10 mg, 15 mg, and 30 mg. Each box contains 1 blister pack (30 tablets).

認証ステータス:

New Animal Drug Application

製品の特徴

ANIPRYL- SELEGILINE HYDROCHLORIDE TABLET
ZOETIS INC.
----------
ANIPRYL
ANIPRYL
(selegiline hydrochloride tablets)
For use in dogs only
CAUTION
Federal law restricts this drug to use by or on the order of a
licensed veterinarian.
DESCRIPTION
Anipryl (selegiline hydrochloride tablets) are white, convex tablets
containing 5, 10, 15,
and 30 mg of selegiline HCl. It is commonly referred to in the
clinical and pharmacological
literature as L-deprenyl (the levorotatory form of deprenyl HCl).
Selegiline hydrochloride is
(—)-_(R)_-_N_,α-Dimethyl-_N_-2-propynylphenethylamine
hydrochloride.
Molecular Formula: C
H
N HCl
Molecular Weight: 223.75
PHARMACOLOGY
Selegiline is an irreversible inhibitor of monoamine oxidase (MAO).
MAOs are widely
distributed throughout the body and are subclassified into 2 types, A
and B, which differ
in their substrate specificity and tissue distribution. Selegiline is
believed to be a selective
inhibitor of MAO-B at recommended dosages in the dog due to its
greater affinity for
type B enzyme active sites compared to type A sites.
In CNS neurons, MAO plays a role
in the catabolism of catecholamines, (dopamine, and, to a lesser
extent, norepinephrine
and epinephrine) and serotonin.
Selegiline may have pharmacologic effects unrelated
®
®
13
17
1,2
1
1,2
to MAO-B inhibition. There is some evidence that it may increase
dopaminergic activity by
other mechanisms, including increasing synthesis and release of
dopamine into the
synapse as well as interfering with dopamine re-uptake from the
synapse.
Effects
resulting from selegiline administration may also be mediated through
its metabolites.
Two of its 3 principal metabolites, L-amphetamine and
L-methamphetamine, have
pharmacologic actions of their own. However, the extent to which these
metabolites
contribute to the effects of selegiline is unknown.
Therapeutic effects of selegiline are thought to result in part from
enhanced
catecholaminergic nerve function and increased dopamine levels in the
CNS.
The
pathogenesis of the development of clinical